Takeda Broadens Gene Therapy Portfolio with Poseida’s Non-Viral Technologies

By Lucy Haggerty

Pharma Deals Review: Vol 2021 Issue 11 (Table of Contents)

Published: 3 Nov-2021

DOI: 10.3833/pdr.v2021.i11.2642     ISSN: 1756-7874

Section: Research & Development



Continuing its interest in gene therapy discovery programmes, Takeda has agreed to pay US$45 M upfront and committed up to US$3...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details